Advanced bioprocess technologies bridge R&D with production. Several players are introducing a wide range of new bioprocessing technologies in the market. On December 4, 2020, IDBS (a provider of software informatics solutions for the biotech and pharmaceutical industries) announced the launch of Polar. Polar creates a new product category called BioPharma Lifecycle Management (BPLM) to streamline drug development and production in biopharma research. Polar is designed and deployed to rapidly solve challenges associated with workflow, process quality, collaboration, and data analysis that have plagued the existing software solutions, including laboratory information management system (LIMS) and electronic laboratory notebook (ELN). As a result, there will be less human errors and an improvement in overall accuracy. It will reduce manual data processing and transcription, leading to fewer human errors and enhanced overall accuracy. It also has extensive search features that make it easier for users to locate what they are searching for, preventing the need for pointless duplication of effort. Merck’s new BioContinuum Platform advances biotherapeutic drug manufacturing through improved efficiency, simplified plant operations, and greater quality and consistency. In addition, Merck’s Pellicon Single-Pass Tangential Flow Filtration aid in intensifying operations associated with the purification of therapeutic proteins. Thus, the introduction of various new-age bioprocess technologies is likely to provide lucrative opportunities for the market growth during the forecast period.
The Saudi Food and Drug Authority (SFDA) has experienced lucrative opportunities that benefit from the National Institute for Bioprocessing Research and Training (NIBRT) that support local biotechnology companies. SFDA is highly focused on biotechnology owing to its high importance toward food and drug production, dependence on agriculture, and food and pharmaceutical products. NIBRT Research is a global leader in the development of innovative technologies and involved in advancing biopharmaceutical manufacturing across multidisciplinary areas such as analytical science, cell and genetic engineering, and bioprocess engineering. Such discoveries are utilized to advance the state of the art by revolutionizing the manufacturing of recombinant proteins, vaccines and cells, and gene therapies.
Middle East & Africa Bioprocess Technology Market Segmentation
The Middle East & Africa bioprocess technology market is segmented into type, modality, end user, and country.
Based on type, the Middle East & Africa bioprocess technology market is segmented into cell culture media bioprocess, chromatography bioprocess, consumables & accessories, and others. In 2023, the consumables & accessories segment registered a largest share in the Middle East & Africa bioprocess technology market.
Based on modality, the Middle East & Africa bioprocess technology market is bifurcated into single use and multiple use. In 2023, the single use segment registered a larger share in the Middle East & Africa bioprocess technology market.
Based on end user, the Middle East & Africa bioprocess technology market is segmented into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. In 2023, the biopharmaceutical companies segment registered a largest share in the Middle East & Africa bioprocess technology market.
Based on country, the Middle East & Africa bioprocess technology market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. In 2023, Saudi Arabia segment registered a largest share in the Middle East & Africa bioprocess technology market.
Danaher Corp; Eppendorf SE; Lonza Group AG; Merck KGaA; Repligen Corp; Sartorius AG; and Thermo Fisher Scientific Inc are the leading companies operating in the Middle East & Africa bioprocess technology market.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 1,233.00 Million |
| Market Size by 2028 | US$ 2,443.75 Million |
| CAGR (2023 - 2028) | 14.7% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2028 |
| Segments Covered |
By Type
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
The Middle East & Africa Bioprocess Technology Market is valued at US$ 1,233.00 Million in 2023, it is projected to reach US$ 2,443.75 Million by 2028.
As per our report Middle East & Africa Bioprocess Technology Market, the market size is valued at US$ 1,233.00 Million in 2023, projecting it to reach US$ 2,443.75 Million by 2028. This translates to a CAGR of approximately 14.7% during the forecast period.
The Middle East & Africa Bioprocess Technology Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Bioprocess Technology Market report:
The Middle East & Africa Bioprocess Technology Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Middle East & Africa Bioprocess Technology Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Middle East & Africa Bioprocess Technology Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+1 646 791 7070
sales@businessmarketinsights.com
Get Free Sample For Middle East & Africa Bioprocess Technology Market
